• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vyome Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    2/25/26 4:15:40 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care
    Get the next $HIND alert in real time by email
    false 0001427570 0001427570 2026-02-20 2026-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 20, 2026

     

    VYOME HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   1-37897   26-1828101
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    Harvard Square, One Mifflin Place, Suite 400

    Cambridge, MA

     

    02138

    (Address of principal executive offices)   (Zip Code)

     

    (949) 429-6680

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Class   Trading Symbol   Name of Exchange on which Registered
    Common stock, $0.001 par value per share   HIND   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    Notes Purchase and Exchange Agreement

     

    As previously reported, on December 17, 2025, Vyome Holdings, Inc. (the “Company”) entered into a binding letter of intent (the “LOI”) regarding a proposed transaction pursuant to which the Company and LiveChain, Inc. (“LICH”), an indirect subsidiary of the Company, agreed to execute definitive agreements to acquire a senior secured convertible note issued by Sociometric Solutions, Inc., d/b/a Humanyze (“Humanyze”) and held by Remus Capital Series B II, L.P. (“Remus”) in exchange for the issuance to Remus of shares of common stock of LICH.

     

    As of February 20, 2026, pursuant to the terms of the LOI, the Company entered into a Notes Purchase and Exchange Agreement (the “Agreement”) by and among LICH, LICH AI Inc. (the “Buyer”), a subsidiary of LICH, and Remus to effectuate the transactions contemplated by the LOI. Pursuant to the Agreement, the Buyer will acquire senior secured convertible notes in the aggregate principal amount of $5,765,000 (the “Notes”) issued by Humanyze and held by Remus. As consideration, LICH will issue to Remus 211,200,844 shares of its common stock, representing 25% of the fully diluted common stock of LICH immediately prior to Closing (as defined in the Agreement). The parties further agreed that immediately following the Closing, all or substantially all of the assets and operations of Humanyze shall be transferred to the Buyer, in full satisfaction of the amounts due and payable to the Buyer under the Notes.

     

    The Agreement provides for the reservation for issuance of up to an additional 84,480,338 shares of LICH’s common stock, representing 10% of the fully diluted common stock of LICH immediately prior to Closing, to key and future employees of LICH (the “Compensatory Shares”). LICH agreed to certain future issuances to Remus, upon issuance of shares by LICH as compensation in consideration of services provided to LICH which obligation to Remus shall terminate upon the earlier of (i) the second anniversary of the Closing; and (ii) the issuance of the Compensatory Shares.

     

    Following the Closing, Remus agreed to ensure that Humanyze remains active and in good standing for purposes of servicing select existing debts, liabilities, and other obligations. In addition, the LICH board of directors and its CEO will use commercially reasonable efforts to raise capital as needed for LICH and/or the Buyer.

     

    The Agreement contains customary representations, warranties and agreements by the parties and customary conditions to closing and obligations of the parties and indemnification provisions. In addition, the Agreement provides for certain termination provisions, including the right of either LICH or Remus to terminate the Agreement in the event that the closing of the transactions contemplated thereby shall not have occurred on or before a certain date (the “Outside Date”). On February 25, 2026, the parties amended the Agreement to update the Outside Date to March 8, 2026.

     

    The Agreement and the transactions contemplated thereunder constitute a related party transaction. Accordingly, the Agreement was reviewed and approved by the Audit Committee of the Board of Directors of the Company prior to its execution. Krishna K. Gupta (founder and CEO of Remus) and John Tincoff (a partner of Remus) recused themselves from the Audit Committee’s deliberations with respect to the Agreement. The Agreement was also reviewed and approved by the Company’s Board of Directors prior to its execution. Mr. Gupta (founder and CEO of Remus), Stash Pomichter (a partner of Remus) and Mr. Tincoff (a partner of Remus) recused themselves from the Board of Directors’ deliberations with respect to the Agreement.

     

    The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.

     

    Item 8.01 Other Events.

     

    On February 24, 2026, the Company issued a press release announcing its entry into the Agreement. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1*   Notes Purchase and Exchange Agreement, dated February 20, 2026, by and among Vyome Holdings, Inc., LiveChain, Inc., LICH AI, Inc., and Remus Capital Series B II, L.P.
    99.1   Press Release issued February 24, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      VYOME HOLDINGS, INC.
         
      By: /s/ Venkat Nelabhotla
        Venkat Nelabhotla
        President & Chief Executive Officer

     

    Dated: February 25, 2026

     

    2

     

    Get the next $HIND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HIND
    SEC Filings

    View All

    SEC Form DEF 14A filed by Vyome Holdings Inc.

    DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/31/26 6:03:52 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Vyome Holdings Inc.

    PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/20/26 4:56:33 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Vyome Holdings Inc.

    10-K - Vyome Holdings, Inc (0001427570) (Filer)

    3/18/26 6:38:57 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pomichter Stanley D Iii

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:10:06 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pomichter Stanley D Iii

    3 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:05:05 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Director Jolly Mohanjit was granted 454,456 shares (SEC Form 4)

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/18/25 6:45:47 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

    VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.

    4/22/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

    Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved

    4/6/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

    Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. "I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can signi

    11/25/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Results of Annual Shareholder Meeting

    All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election – Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter – were re-elected to serve on Vyome's board until the 2028 annual shareholder meeting, with 93% of the votes being cast in favor. "This vote of confidence from shareholders ensures that Vyome's strong, innovative DNA of MIT alums remains intact for years to come. None of the Independent board members is taking any cash compensation or any new equity grants (other than grants

    11/4/25 9:04:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

    Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved

    9/9/25 8:30:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Financials

    Live finance-specific insights

    View All

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

    (Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations. Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials. Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies. Launched AI strategy with the acquisition of MIT startup Oculo Vyome Holdings, I

    11/18/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Acquires MIT AI Spinout Oculo Health

    Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Dire

    9/29/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care